Prof Oliver Ottmann talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about HSCT in Ph-positive ALL and how it is still the most dependable form of therapy.

Prof Ottmann understands that not every patient is suitable for transplant but with advancements in technology we have seen an improved supportive care, an increase in patient age and an improvement in donor matching.

He goes on to say how both he and his 'opponent' in the debate, Prof Robin Foa, agree that you have to individualise each decision based on the case.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.